BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 11677850)

  • 1. [Difficulties with conducting clinical trials in France].
    Zannad F; Plétan Y
    Therapie; 2001; 56(4):341-7. PubMed ID: 11677850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Organisation of clinical research in France: the new missions of inter-regional delegations for clinical research].
    Jaillon P
    Bull Acad Natl Med; 2008 May; 192(5):929-37; discussion 937-9. PubMed ID: 19238783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical doctors profile in Ethiopia: production, attrition and retention. In memory of 100-years Ethiopian modern medicine & the new Ethiopian millennium.
    Berhan Y
    Ethiop Med J; 2008 Jan; 46 Suppl 1():1-77. PubMed ID: 18709707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the exception from informed consent regulations in research.
    Mosesso VN; Cone DC
    Acad Emerg Med; 2005 Nov; 12(11):1031-9. PubMed ID: 16264070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [How to improve patients and investigators' information on clinical trials: the example of French registry for clinical trials in oncology].
    Pauporté I; Manach E; Bachouche N; Hommais A; Détry S; Legrand-Lane C; Barbare JC
    Bull Cancer; 2008 Dec; 95(12):1227-32. PubMed ID: 19091658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Opinion of the French National Academy of Medicine on the legislative framework for the application of the European Directive on biomedical research in humans].
    Rouëssé J
    Bull Acad Natl Med; 2003; 187(5):1001-15. PubMed ID: 14979061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seeking informed consent to cancer clinical trials: describing current practice.
    Brown RF; Butow PN; Ellis P; Boyle F; Tattersall MH
    Soc Sci Med; 2004 Jun; 58(12):2445-57. PubMed ID: 15081196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical research and Huriet's law in medical oncology. Results of a French investigation among medical oncologists].
    Hoerni B
    Bull Cancer; 1997 Mar; 84(3):305-10. PubMed ID: 9207877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Attractiveness of France for international clinical trials in 2012: 6(th) survey assessed by Leem (French association of pharmaceutical companies)].
    Lassale C; Sibenaler C; Béhier JM; Barthélémy P; Plétan Y; Courcier S
    Therapie; 2013; 68(1):1-18. PubMed ID: 23484655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seeking informed consent to cancer clinical trials; evaluating the efficacy of doctor communication skills training.
    Brown RF; Butow PN; Boyle F; Tattersall MH
    Psychooncology; 2007 Jun; 16(6):507-16. PubMed ID: 16986176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recruiting minorities where they receive care: Institutional barriers to cancer clinical trials recruitment in a safety-net hospital.
    Joseph G; Dohan D
    Contemp Clin Trials; 2009 Nov; 30(6):552-9. PubMed ID: 19580887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The analysis of physicians' work: announcing the end of attempts at in vitro fertilization].
    Santiago-Delefosse M; Cahen F; Coeffin-Driol C
    Encephale; 2003; 29(4 Pt 1):293-305. PubMed ID: 14615699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.